Research programme: cannabinoid receptor CB1 antagonists - Evotec AGAlternative Names: Cannabinoid receptor CB1 antagonists - Evotec AG
Latest Information Update: 16 Sep 2008
At a glance
- Originator Evotec AG
- Mechanism of Action Cannabinoid receptor CB1 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 16 Sep 2008 Discontinued - Preclinical for Obesity in Germany (unspecified route)
- 12 Sep 2007 Preclinical trials in Obesity in Germany (unspecified route)